1. Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells
- Author
-
Jiaojiao Yang, Liyue Sun, Xiao‐Yun Liu, Chan Huang, Junling Peng, Xinxin Zeng, Hailin Zheng, Wenjian Cen, Yu‐Xia Xu, Weijie Zhu, Xiao‐Yan Wu, Dongyi Ling, Lu‐Lu Zhang, Mingbiao Wei, Ye Liu, Deshen Wang, Feng‐Hua Wang, Yu‐Hong Li, Qin Li, and Ziming Du
- Subjects
Breast cancer ,CDO1 ,epigenetic editing ,serum methylation biomarker ,targeted demethylation system ,Medicine (General) ,R5-920 - Abstract
Abstract Background Cysteine dioxygenase 1 (CDO1) is frequently methylated, and its expression is decreased in many human cancers including breast cancer (BC). However, the functional and mechanistic aspects of CDO1 inactivation in BC are poorly understood, and the diagnostic significance of serum CDO1 methylation remains unclear. Methods We performed bioinformatics analysis of publicly available databases and employed MassARRAY EpiTYPER methylation sequencing technology to identify differentially methylated sites in the CDO1 promoter of BC tissues compared to normal adjacent tissues (NATs). Subsequently, we developed a MethyLight assay using specific primers and probes for these CpG sites to detect the percentage of methylated reference (PMR) of the CDO1 promoter. Furthermore, both LentiCRISPR/dCas9‐Tet1CD‐based CDO1‐targeted demethylation system and CDO1 overexpression strategy were utilized to detect the function and underlying mechanism of CDO1 in BC. Finally, the early diagnostic value of CDO1 as a methylation biomarker in BC serum was evaluated. Results CDO1 promoter was hypermethylated in BC tissues, which was related to poor prognosis (p
- Published
- 2023
- Full Text
- View/download PDF